NCT06961266 is a Phase 1 clinical trial of JZP441 in Narcolepsy, sponsored by Jazz Pharmaceuticals.

Who is sponsoring NCT06961266?

NCT06961266 is sponsored by Jazz Pharmaceuticals.

What drugs are being tested in NCT06961266?

Interventions in NCT06961266: JZP441, Matching Placebo.

What condition does NCT06961266 study?

NCT06961266 studies Narcolepsy.

Is NCT06961266 still recruiting?

NCT06961266 is currently terminated. Last updated 6 April 2026.

Last reviewed 2026-04-06 · How we verify

NCT06961266

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1

Terminated Phase 1 Last updated 6 April 2026

What this trial tests

Phase 1 trial testing JZP441 in Narcolepsy in 6 participants. Terminated before completion.

Timeline

13 May 2025

Primary endpoint
29 January 2026

29 January 2026

Quick facts

Lead sponsor	Jazz Pharmaceuticals
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	6
Start date	13 May 2025
Primary completion	29 January 2026
Estimated completion	29 January 2026
Sites	4 locations across United States

Drugs / interventions tested

JZP441 — full drug profile →
Matching Placebo — full drug profile →

Conditions studied

Narcolepsy — all drugs for Narcolepsy →

Sponsor

Jazz Pharmaceuticals — full company profile →

Who can join

Adults 18 to 64, any sex, with Narcolepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Narcolepsy is a sleep disorder in which patients are not able to maintain wakefulness or require treatment to maintain wakefulness during the daytime. Narcolepsy is a lifelong neurologic disease for which no cure has been clinically available. JZP441 is currently being developed for the treatment of narcolepsy type 1 (NT1). This study will assess the safety of efficacy of JZP441 in adult patients with NT1.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hypocretin: a promising target for the regulation of homeostasis.
Wang Y, Fu S, Mao J, Cui K, et al · · 2025 · cited 2× · PMID 40927422 · DOI 10.3389/fnins.2025.1638270

Verify or expand the search:

Other trials of JZP441

Trials testing the same drug.

NCT05720494 — A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Parti · Phase 1 · completed
NCT05651152 — A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Heal · Phase 1 · completed

Other recruiting trials for Narcolepsy

Currently open trials in the same condition.

NCT06797284 — The Impact of Light, Electrical, and Magnetic Neuroregulation Interventions on Sleep-wake Disorders · NA · recruiting
NCT06586138 — Study of Psychological, Sociological and Professional Factors Associated With Maintenance of Wakefulness Test · recruiting
NCT04806620 — Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research · recruiting
NCT05615584 — Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence · NA · recruiting
NCT06279247 — Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy · recruiting

Other Jazz Pharmaceuticals trials

Trials by the same sponsor.

NCT07533942 — A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma · Phase 2 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting
NCT07377539 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants · Phase 1 · not yet recruiting
NCT07282587 — Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma · Phase 2 · recruiting
NCT07233239 — A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06961266 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jazz Pharmaceuticals
Last refreshed: 6 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06961266.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing